By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Cancer Research Technology Ltd. et al. v. Sun Pharma Global FZE et al.
3:10-cv-04745; filed September 15, 2010 in the District Court of New Jersey
• Plaintiffs: Cancer Research Technology Ltd.; Schering Corp.
• Defendants: Sun Pharma Global FZE; Sun Pharmaceutical Industries, Inc.
Infringement of U.S. Patent No. 5,260,291 ("Tetrazine Derivatives," issued November 9, 1993) following a Paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of plaintiffs' Temodar® (temozolomide, used to treat brain tumors). View the complaint here.
Astrazeneca Pharmaceuticals, et al. v. Osmotica Pharmaceutical Corp.
7:10-cv-00183; filed September 13, 2010 in the Eastern District of North Carolina
• Plaintiffs: AstraZeneca Pharmaceuticals LP; AstraZeneca UK Ltd.
• Defendants: Osmotica Pharmaceutical Corp.
Infringement of U.S. Patent Nos. 4,879,288 ("Novel Dibenzothiazepine Antipsychotic," issued November 7, 1989) and 5,948,437 ("Pharmaceutical Compositions Using Thiazepine," issued September 7, 1999) following a Paragraph IV certification as part of Osmotica's filing of an ANDA to manufacture a generic version of AstraZeneca's Seroquel® XR (quetiapine fumarate, used to treat schizophrenia and bipolar disorder). View the complaint here.
Yeda Research and Development Co., Ltd. v. Abbott GMBH & Co. KG
1:10-cv-01518; filed September 9, 2010 in the District Court of the District of Columbia
Review of the decision of the Board of Patent Appeals and Interferences awarding priority of invention to Abbott in the interference between U.S. Patent Application No. 07/930,443 ("Tumor Necrosis Factor Binding Protein II, Its Purification and Antibodies Thereto," filed August 19, 1992), assigned to Yeda and U.S. Patent No. 5,344,915 ("Proteins and the Preparation Thereof," issued September 6, 1994), assigned to Abbott. View the complaint here.
Comments